drugset / Trial / NCT03169881

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

NCT03169881

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo

Timeline

Start
2017-09-20
Primary completion
2022-12-23
Completion
2025-05-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 10 ug/kg Intravenous